Phase III Trial Exploring the Combination of Bevacizumab and Lomustine in Patients With First Recurrence of a Glioblastoma

Trial Profile

Phase III Trial Exploring the Combination of Bevacizumab and Lomustine in Patients With First Recurrence of a Glioblastoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Lomustine
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jul 2017 Planned End Date changed from 1 Oct 2016 to 1 Oct 2017.
    • 06 Jul 2016 Planned End Date changed from 1 Apr 2016 to 1 Oct 2016.
    • 07 Jun 2016 Results (n=274) assessing sequencing of bevacizumab and lomustine in subjects with first recurrence of a glioblastoma presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top